{"analyses":[{"groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":".0009","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2"},{"groupId":"OG001","value":"11.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"The proportion of subjects who achieved platelet \\>100 x 10\\^9/L or increase ≥50% over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors.","groups":[{"description":"Ibrutinib 420 mg daily.","id":"OG000","title":"Ibrutinib"},{"description":"Chlorambucil 0.5 mg/kg (to maximum 0.8 mg/kg) days 1 and 15 of 28-day cycle up to 12 cycles","id":"OG001","title":"Chlorambucil"}],"paramType":"NUMBER","populationDescription":"Intention to treat","reportingStatus":"POSTED","timeFrame":"Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.","title":"Proportion of Sustained Platelet Improvement","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}